247 related articles for article (PubMed ID: 26098782)
1. Adaptive Phase I clinical trial design using Markov models for conditional probability of toxicity.
Fernandes LL; Taylor JM; Murray S
J Biopharm Stat; 2016; 26(3):475-98. PubMed ID: 26098782
[TBL] [Abstract][Full Text] [Related]
2. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
[TBL] [Abstract][Full Text] [Related]
4. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
[TBL] [Abstract][Full Text] [Related]
5. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
Muenz DG; Braun TM; Taylor JM
Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
[TBL] [Abstract][Full Text] [Related]
6. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
Zhao D; Zhu J; Wang L
Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
[TBL] [Abstract][Full Text] [Related]
7. Multivariate Markov models for the conditional probability of toxicity in phase II trials.
Fernandes LL; Murray S; Taylor JM
Biom J; 2016 Jan; 58(1):186-205. PubMed ID: 26250444
[TBL] [Abstract][Full Text] [Related]
8. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
9. Dose finding with continuous outcome in phase I oncology trials.
Wang Y; Ivanova A
Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
[TBL] [Abstract][Full Text] [Related]
10. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials.
Shi H; Cao J; Yuan Y; Lin R
Stat Med; 2021 May; 40(11):2626-2649. PubMed ID: 33650708
[TBL] [Abstract][Full Text] [Related]
11. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.
Zhang L; Yuan Y
Stat Med; 2016 Nov; 35(27):4924-4936. PubMed ID: 27580928
[TBL] [Abstract][Full Text] [Related]
12. Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information.
Zhang Y; Kutner M; Chen Z
Biom J; 2021 Oct; 63(7):1476-1492. PubMed ID: 33969525
[TBL] [Abstract][Full Text] [Related]
13. Practical model-based dose-finding in phase I clinical trials: methods based on toxicity.
Thall PF; Lee SJ
Int J Gynecol Cancer; 2003; 13(3):251-61. PubMed ID: 12801254
[TBL] [Abstract][Full Text] [Related]
14. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.
Bekele BN; Shen Y
Biometrics; 2005 Jun; 61(2):343-54. PubMed ID: 16011680
[TBL] [Abstract][Full Text] [Related]
15. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials.
Gönen M
Contemp Clin Trials; 2005 Apr; 26(2):131-40. PubMed ID: 15837436
[TBL] [Abstract][Full Text] [Related]
16. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
Tighiouart M; Cook-Wiens G; Rogatko A
J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
[TBL] [Abstract][Full Text] [Related]
17. A Bayesian approach to dose-finding studies for cancer therapies: incorporating later cycles of therapy.
Sinclair K; Whitehead A
Stat Med; 2014 Jul; 33(15):2665-80. PubMed ID: 24590816
[TBL] [Abstract][Full Text] [Related]
18. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
Koopmeiners JS; Modiano J
Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
[TBL] [Abstract][Full Text] [Related]
19. Escalation with overdose control for phase I drug-combination trials.
Shi Y; Yin G
Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
[TBL] [Abstract][Full Text] [Related]
20. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.
Ji Y; Wang SJ
J Clin Oncol; 2013 May; 31(14):1785-91. PubMed ID: 23569307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
